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1.1 NEUROENDOCRINE TUMORS OF THE LUNG 
Neuroendocrine tumors (NET) of the lung represent a distinctive family of lung tumors with shared 
characteristics. The four major categories of NET of the lung are small cell lung carcinoma 
(SCLC), large cell neuroendocrine carcinoma (LCNEC), typical carcinoid (TC) and atypical 
carcinoid (AC) [1]. While the first two are considered high-grade tumors, the last two are 
considered to be low and intermediate-grade malignant tumors respectively [2-4]. There is 
increasing evidence that TC and AC are morphologically associated more closely with each other 
than with LCNEC and SCLC. In fact, from a clinical standpoint, approximately 40% of patients 
with either AC or TC are non-smokers, while almost all patients affected by SCLC or LCNEC are 
heavy smokers. Moreover, unlike the high-grade lesions, both AC and TC can occur in 8% of 
patients with multiple neuroendocrine neoplasia type 1 (MEN 1) and show MEN 1 mutations in 
sporadic cases (40%) [5,6]. In addition, diffuse idiopathic pulmonary neuroendocrine cell 
hyperplasia (DIPNECH), with or without tumorlets, may be present in both typical and atypical 
carcinoids, for which it is considered a preneoplastic lesion, but is not a defined preneoplastic 
lesion for SCLC or LCNEC. 
 
1.2 CARCINOID TUMORS OF THE LUNG 
These are neuroendocrine epithelial malignancies, which can be divided in two categories: typical 
carcinoind (TC) with < 2 mitoses per 2mm2 with a diameter ≥ 0.5cm and lacking necrosis and 
atypical carcinoid (AC) with 2-10 mitoses per 2mm2 and/or foci of necrosis. These are relatively 
rare malignancies with an estimated age-adjusted incidence that ranges from <0.1 per 100.000 to 
1.5 per 100.000, with TC accounting for 70-90% of cases. The incidence of carcinoid tumors is 
higher in Caucasian non-smokers females and aged <60 years old [7]. The mechanisms of 
carcinoid tumors development and progression are not clear, although some cases are postulated 
to develop in the MEN1 setting; others are assumed to develop in the setting of DIPNECH and 
tumorlets [8]. Carcinoids are rarely associated with DIPNECH and may rarely produce a military 
pattern in the lung [9]. The cell of origin is unknown, although it was historically thought to arise 
from pulmonary neuroendocrine (Kluchitsky) cells. Carcinoid tumors of the lung most commonly 
arises in the central airways with peripheral forms accounting for 1/3 of cases and can be 
asymptomatic and incidentally detected. Most central carcinoids are found in mainstem or lobar 
bronchi, peripheral carcinoid tumors are more likely to be AC. Peripheral TC in particular may be 
associated with multiple tumorlets with or without DIPNECH. Clinical syndromes underlying a 
peptide production are uncommon and include carcinoid syndrome, acromegaly and Cushing 
syndrome. The classic VIII TNM staging system is applied to carcinoid tumors though lymphatic 
and distant haematogenous metastases are encountered more frequently with the AC form. 
Atypical carcinoid has a worse prognosis than TC with a 5-years survival rate that is approximately 
90% for TC and 60% for AC [10,11]. Prognostic factors are considered also TNM stage and 
mitotic index. In resectable cases prognosis depends mostly on complete surgical resection.  
 
1.3 PRE-INVASIVE NEUROENDOCRINE LESIONS OF THE LUNG 
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) represents a 
generalized proliferation of pulmonary neuroendocrine cells (PNCs) that may be confined to the 
mucosa of airways (with or without luminal protrusion), may invade locally to form tumorlets, or 
may develop into carcinoid tumors (Fig.1) [1]. Indeed, tumorlets are defined as locally infiltrative 
(microinvasive) well differentiated pulmonary neuroendocrine micro-tumors measuring up to 0.5 
cm and are considered potential precursor proliferations for TC and AC [1,12]. DIPNECH is often 
accompanied by mild chronic lymphocytic inflammation and fibrosis of the involved airways (in 
form of constrictive bronchiolitis). In fact, DIPNECH has been frequently associated with 
pulmonary fibrosis and bronchiectasis, suggesting that it may represent a hyperplastic response of 
pulmonary neuroendocrine cells to airways impairment and hypoxia [13-19]. Cytokines and 
growth factors secreted by PNCs (such as bombesin, gastrin releasing peptide, and fibroblast 
growth factor), stimulate fibrosis and airway cell chemotaxis, which results in bronchiolar fibrosis 
and obstructive patters at pulmonary function tests [20]. In some cases, the presence of allergy-
like symptoms has been reported from the patients for many years before diagnosis (pruritus, nasal 
congestion, lachrymation, asthma), probably as a consequence of the secretion of hormones and 
neuropeptides from pulmonary neuroendocrine cells of the so-called diffuse neuroendocrine 
system [21]. Moreover, DIPNECH can be diagnosed in two different clinical settings: the first, in 
symptomatic patients presenting with respiratory symptoms (dry cough, exertion dyspnea, and 
wheezing, often misdiagnosed as asthma) with a suspicious high resolution CT-scan, often 
evolving in progressive respiratory insufficiency; the latter, as an incidental finding at the 
histologic examination in asymptomatic patients after surgery for carcinoid tumors [21-24]. 
Pathological examination is the gold standard for the diagnosis, however when widespread PNCs 
proliferation is denoted in the non-neoplastic lung surrounding a TC but the diagnosis of 
DIPNECH is not certain, high-resolution CT may be useful, showing nodular bronchial wall 
thickening, mosaic attenuation caused by mucus plugging, airway obstruction, air trapping, and 
sometimes bronchiectasis [20].  DIPNECH probably arises in terminal bronchioles as a cluster of 
neuroendocrine cells; when tumorlets develop, invading the basal lamina, they extend through the 
bronchiolar wall. It is not known what proportion of DIPNECH patients eventually develop 
carcinoid tumors, but it is probably the minority. Most of tumors that develops in this context are 





1.4 MULTIFOCAL PULMONARY NEUROENDOCRINE PEOFLIFERATIONS 
Synchronous multifocal microscopic pulmonary neuroendocrine proliferations (MNEP) represent 
a subgroup of diagnostic entities comprehending DIPNECH and well-differentiated pulmonary 
neuroendocrine micro-tumors (also known as tumorlets or micro-carcinoids) combining in 
different patterns [11,20,25-27] and possibly leading to the simultaneous formation of carcinoid 
tumors. As said, DIPNECH can show multifocal pulmonary neuroendocrine cell hyperplasia-to-
neoplasia progression sequence characterized by multiple micro-neuroendocrine tumors 
(tumorlets) as well differentiated pulmonary neuroendocrine tumors [28,29], therefore it is 
considered a preinvasive lesion [1]. The multifocal combination of these complex, evolutive 
patterns defines MNEP (Fig.1). It should be emphasized that, in the setting of DIPNECH (and 
consequently MNEP), multiple carcinoid tumors should not be regarded as metastatic lesions, but 
as synchronous multiple primaries [22].   
 
1.5 AIM OF THE STUDY 
The biological significance of MNEP in association with well-differentiated pulmonary 
neuroendocrine tumors with low-grade proliferative features (TC), is still a matter of debate 
[13,30]. Therefore, MNEP has been reported in sporadic cases, and their incidence and prevalence 
remain to be established along with their clinic-pathological significance, yet not evaluated in large 
series. To address this knowledge gap, we analyzed the clinic-pathological features of a 
comprehensive series of surgically treated well-differentiated pulmonary neuroendocrine tumors. 
Aim of the study was to assess the prevalence of MNEP and to define the prognostic value of 
MNEP in patients who underwent pulmonary resection for TC. Meanwhile, the association 
between MNEP and the underlying chronic lung inflammatory disease and the potential role of 
inhalant exposure in our study population has been described. 
 
2. PATIENTS AND METHODS 
 
2.1 STUDY DESIGN 
We have analyzed the institutional database from the Thoracic Surgery Department, University of 
Perugia, Perugia, PG, Italy (between Jan 1983 and Dec 2013) and the Department of Thoracic 
Surgery, University Health Network, Toronto, ON, Canada (between Jan 2000 to Dec 2013) 
including over 350 patients operated for well-differentiated pulmonary neuroendocrine tumors.  
Patients with atypical carcinoid tumor, presence of synchronous or previous primary/metastatic 
tumor, biopsy or isolated bronchoplasty specimens with pulmonary neuroendocrine tumors, as 
well as lung transplants, patients with a follow-up period of less than 5 years and patients with 
neoadjuvant chemo/radiotherapy were excluded.   
Standard diagnostic workup included chest-abdomen CT scan and fiberoptic bronchoscopy. 
111In-pentetreotide scan (OctreoScan) was performed from 1996 and 18FDG/PET-CT from 2004. 
We defined central lesions those located in segmental or larger bronchus and peripheral tumors 
those involved with the subsegmental bronchus or beyond. Preoperative histologic diagnosis was 
achieved by bronchial biopsy in centrally-located lesions and by fine needle aspiration biopsy or 
by video-assisted wedge resection in peripheral lesions. Mediastinoscopy or endobronchial 
ultrasound (EBUS) were carried out in patients with CT scan finding of mediastinal node 
enlargement or in those glucose avid at 18FDG/PET-CT. Endobronchial debridment in rigid 
bronchoscopy was performed pre-operatively to assess tumor location and treat obstructive 
pneumonia in selected cases. Surgery consisted of sub-lobar, lobar, bronchial sleeve lobectomy 
and pneumonectomy. Nodal sampling was usually performed during sub-lobar resections, while 
systematic or lobe-specific lymphadenectomy were carried out along with major resections. 
NE differentiation was assessed on the basis of morphology and immunohistochemical reactivity 
for panneuroendocrine markers Neuron Specific Enolase (NSE), Chromogranin A, 
Synaptophysin. In each case, the presence of necrosis, number of mitoses, and Ki-67 index were 
evaluated. Multiple forms and tumorlets were carefully researched by performing serial sections 
of lung parenchyma.  
Staging was established according to the 8th edition of the AJCC TNM staging system. 
The follow-up protocol included clinical interview with physical examination, chromogranine A 
measurements, chest-abdomen CT scan at 6 months, 1 year and 2 years after surgery. Then annual 
chest X-ray, abdomen ultrasonography and biochemistry profile were performed; chest-abdomen 
CT scan was indicated every 2 years for at least 15 years. Fiberoptic bronchoscopy was performed 
yearly for the first 2 years and then every 3 years for patients with central tumors and every 5 years 
for peripheral TC.  
Parameters related to patient’s demographics (age at the time of surgery, gender) and clinical 
history (smoking history, body mass index, gastro-esophageal reflux disease, chronic obstructive 
pulmonary disease, Charlson co-morbity index, occupational exposure to inhalants gas, dust or 
fumes, respiratory symptoms related to asthma or bronchitis) were collected. Theragnostic 
considered imaging details (tumor location, absence or presence of synchronous micronodules on 
the preoperative chest CT); the type of surgical procedure (sub-lobar, lobar, bronchial sleeve 
lobectomy and pneumonectomy); the type of lymphadenectomy (systematic, lobe-specific, 
sampling and no lymphadenectomy); along with histopathological data (tumor size, nodal status, 
tumor stage, status of non-tumorous lung parenchyma by analysis of chronic inflammation, 
fibrosis, emphysema and bronchiolitis) were considered.  
The OS was calculated from the date of surgery to the last date of follow-up (for alive patients) or 
the date of death. The PFS was calculated from the date of surgery to the date of recurrence.  
A total of 234 patients affected by primary lung TC were enrolled; among these 41 (17.52%) had 
MNEP along with single TC (MNEP+TC) and 193 had only TC. The two groups were compared. 
Given the heterogeneity of a number of baseline variables between groups, a 1:1 propensity score 
matching was used to compare the long-term survival data between TC and MNEP+TC. Age at 
time of diagnosis, tumor stage, smoking history, location, follow-up time, patients’ clinical 
management site (Toronto vs Perugia), side and size of the primary tumor were entered as 
independent variables in the logistic regression model. The study design is displayed in Figure 2.  
 
2.2 STATISTICAL ANALYSIS 
 
Unmatched Data 
Data on categorical variables were reported as frequencies and percentages. Continuous variables 
were described as means +/- standard deviations, along with median values. Summary statistics 
are reported on the whole cohort and also on patients with or without hyperplasia individually. 
Statistical significance was reported using Chi-square test for categorical variables and student’s 
t-test for continuous data. Kaplan-Meier method was used to estimate the probability of OS and 
PFR, and log-rank test was used to report significance between groups. Cox regression model was 
used to identify significant independent predictors of the OS. The statistical significance level was 
chosen at a p value of 0.05 or less. SAS v9.3 (SAS Institute, Cary NC, USA) or R version 3.3.3 
(R Core Team,2013; R: A language and environment for statistical computing; R Foundation for 







Among the 41 patients in the MNEP+TC group, 36 patients could be matched with TC group. This 
resulted in 36 matched pairs for the comparison of patients with MNEP+TC and TC. Patients then 
were matched on the logit of the propensity score using a caliper of 0.2 standard deviations of the 
logit of the propensity score. The percentage of GMATCH propensity score macro developed by 
the Division of Biostatistics at the Mayo Clinic was used for propensity score matching [31]. 
To assess the balance between matched samples, standardized differences were calculated and 
used in this report [32]. Some authors have suggested that standardized differences of less than 0.1 
(10%) likely denote a negligible imbalance between treated and untreated subjects [33]. 
The OS and PFR were compared between matched groups, by using a robust variance estimator 
in univariable Cox regression model. In the matched group analysis, association of clinical, 
respiratory and work-related factors with group category (MNEP+TC vs TC) was determined 
through univariable and multivariable conditional logistic regression analysis and the associated 
p-values were reported. 
 
2.3 INSTITUTIONAL REVIEW BOARD APPROVAL  
IRB approvals were obtained for both data sites from the department of Thoracic Surgery, 
University of Perugia (Comitato Etico Aziende Sanitarie Umbria Prot. 8579/16/L, Perugia, PG, 
Italy) and for the Department of Thoracic Surgery at the Toronto General Hospital (Research 
Ethics Board 12-5628-TE, University Health Network, Toronto, ON, Canada). All patients signed 
the permission for anonymous use of their clinical data for scientific purposes; a formal informed 




Amongst 41 patients with MNEP+TC, we identified 5 patients with PNECH, 16 patients with 
tumorlets and 20 patients affected by tumorlets/microcarcinoids along with PNECH. Eleven of 41 
patients had preoperative evidence of micronodules on imaging studies, and 6 of them were 
radiologically evident in different lobe or in the controlateral lung. Patients in the MNEP+TC 
group were characterized by older age (63±1 years vs 54±1 years, p<0.001), peripheral tumors 
(76% vs 50%, p=0.0032), smaller tumor size (16.2±10.9 mm vs 21.3±11.7 mm, p=0.011) and 
lymph-nodal spread (p=0.02) in comparison with TC group. Clinical and pathological features of 
the 234 patients are displayed in Table 1. 
 
3.1 RECURRENCE AND SURVIVAL 
The mean follow-up period was 9.6±5.2 years (range 1.4-31.3 years). Fifteen people had relapse: 
8 in the MNEP+TC group (19.5%) and 7 in the TC group (3.6%). The pattern of relapse was the 
following: liver (8), endobronchial (3), bones (4), brain (2) and lung (1). Among the 6 patients in 
MNEP+TC group with radiologically evident micronodules in different lobe or in the controlateral 
lung one regressed, 4 remained stable and one increased in size; this patient underwent 
lingulectomy 6 years after right upper lobectomy. Two hundred six patients were alive and 28 
died: 4 disease related out of 12 MNEP+TC patients (33.3%) and none disease related out of 16 
TC. The 10-years PFR was higher in the TC group (96.1%) than in the MNEP+TC group (83.8%) 
(p<0.001). The 10-years OS was better for TC patients (93.5%) compared to MNEP+TC patients 
(71.9%) (p<0.001).The OS and PFR curves are shown in Figure 3. Figure 4 graphically displays, 
in a Forest Plot, the estimated results pooled by two groups (MNEP+TC vs TC). 
 
 
3.2 UNI-MULTIVARIABLE ANALYSIS 
The univariable regression analysis demonstrated that MNEP+TC was the only prognostic factor 
influencing negatively the PFR [p=0.0017, HR 5.8 95%CI 1.93-17.4]. This was confirmed also by 
comparing each sub-group analyses: Perugia-MNEP+TC versus TC alone [p=0.0044, HR 0.13 
95% CI 0.03-0.53] and Toronto-MNEP+TC versus TC alone [p=0.027, HR 0.18 95% CI 0.04-
0.82]. With regard to OS, the univariable regression analysis revealed that MNEP+TC [p<0.001, 
HR 4.78 95%CI 2.23-10.23] and age older than 65 years [p=0.022, HR 2.41 95%CI 1.14-5.11] 
were poor prognostic factors. At the multivariable analysis only MNEP+TC [p<0.001, HR 3.71 
95%CI 1.08-12.68] confirmed to be independent prognostic factor.  
 
3.3 PROPENSITY SCORE MATCH ANALYSIS 
Among the 41 patients with MNEP+TC, 36 patients could be matched with the TC group on the 
basis of age, stage, location, smoking history and follow-up time (Figure 2).  This resulted in 36 
matched pairs for the comparison of MNEP+TC vs TC groups. Table 2 summarizes the baseline 
characteristics of patients in the propensity score matched sample, along with the associated 
standardized differences in both the matched sample and the initial sample. The standardized 
differences were all smaller in matched sample compared to the original sample. The largest 
standardized difference in the matched sample was 0.17 for gender, and the largest standardized 
difference in the original sample was 0.54 for location. Primary matched variables of interest 
between TC and MNEP+TC groups included age at time of diagnosis, tumor stage, tumor location, 
smoking history and follow-up time. All primary variables of interest had standardized difference 
less than or equal to 0.15 in the matched sample. Amongst the 36 matched pairs, tumor progression 
was recorded in 6 patients of the MNEP+TC group (16.6%). Thirty-two patients were alive in the 
TC group as opposed to 24 in the MNEP+TC group. The 5-years PFR was higher in the TC group 
(100%) than in the MNEP+TC group (93.4%).When a univariate Cox proportional hazards model 
was fit and robust variance estimator was obtained, the associated p-value for the comparison of 
MNEP+TC with TC was <0.001. However, hazard ratios could not be obtained, as the TC group 
did not have any events.The 5-years OS was similar for TC patients (91.3%) and MNEP+TC 
patients (93.8%). When a univariate Cox proportional hazards model was fit and robust variance 
estimator was obtained, the associated hazard ratio for MNEP+TC compared to TC was 2.78 (95% 
CI=0.84-9.3, p=0.095).  The OS and PFR curves for the matched groups are shown in Figure 5. 
In the matched population, the univariable conditional logistic regression analysis demonstrated 
that the odds of belonging to MNEP+TC group was higher with the different following factors. 
Occupational exposure to inhalant gas, dust or fumes [p=0.008; OR 5.33; 95%CI 1.55-18.30]. 
Presence of respiratory symptoms-related to asthma/bronchitis[p=0.002;OR795%CI2.09-23.47]. 
Bronchiectasis/Fibrosis/Emphysema/Granuloma/Pneumonitis (BFEGP) pattern [p=0.032; OR 4; 
95%CI 1.13-14.18]. Finally, the presence of micronodules on the pre-operative chest CT scan 
[p=0.039; OR 3.25; 95%CI 1.06-9.96].  
Conversely, the odds declined with the presence of an increased oxygen partial pressure in the 
arterial blood gas analysis [p<0.036; OR 0.95; 95%CI 0.91-0.99]. At the multivariable analysis, 
we considered two types of conditional logistic regression analysis: clinical (MODEL-1) and 
pathological (MODEL-2). In MODEL-1 the occurrence of respiratory symptoms-related to asthma 
or bronchitis [p=0.009; OR 6.94; 95%CI 1.60-30.1] and presence of micronodules on the pre-
operative chest CT scan [p=0.043; OR 4.54; 95%CI 1.05-19.6] resulted to be independent 
predictors of MNEP. 
In MODEL-2 work exposure to inhalant gas, dust or fumes [p=0.026; OR 5; 95%CI 1.21-20.5] the 
presence of micronodules on the pre-operative chest CT scan [p=0.042; OR 4.86; 95%CI 1.06-
22.2] and BFEGP patterns [p=0.03; OR 5.96; 95%CI 1.18-29.9] resulted to be independent 
predictors of MNEP. 
 
4. DISCUSSION 
The knowledge gap regarding to the incidence and clinical significance of MNEP in association 
with TC and their clinico-pathologic correlates in larger series was one of the main drivers of this 
study. After the first description of DIPNECH [34], small series and case reports have been 
published in Literature (Table 3), but the complex pathophysiology and the real clinical meaning 
remain to be better clarified [35-37]. The current surgical series identified MNEP in 17.5% of 
patients with TC. In the MNEP+TC group older age (p<0.001), peripheral tumors (p=0.0032), 
smaller tumor size (p=0.011) and lymph-nodal spread (p=0.02) were observed in comparison with 
TC group. The findings of this cohort also showed that this pattern was significantly associated 
with adverse outcome in affected patients as represented by a trend of progressively reduced 10-
year OS and PFR rates when compared to patients with TC: the 10-years progression-free survival 
were 96.1% in TC and 83.8% in MNEP+TC groups (p<0.001). Also in the matched population the 
5-year PFR in the group with MNEP+TC resulted to be significantly lower compared to patients 
of TC group (p<0.01). Moreover, relapses occurred in 8 patients (19.5%) in the MNEP+TC group 
and in 7 (3.6%) of the TC group. Another important highlight from the current series is the 
presence of statistically significant association of asthma/bronchitis, work exposure to inhalant 
agents, emphysema, fibrosis and inflammatory status and respiratory insufficiency with 
MNEP+TC. Specifically, the significance in MNEP+TC group was higher with work-related 
exposure to inhalant agents (p=0.008), asthma/bronchitis (p=0.002), emphysema, fibrosis and 
inflammatory status (p=0.032), micronodules on the chest CT-scan and respiratory insufficiency 
(p=0.036).  
 
To discuss this issue properly, we articulate our concepts in four distinct paragraphs. 
 
 
The role of the thin slice CT and Nuclear medicine imaging in preoperative diagnosis and 
postoperative follow-up 
Assessment of preoperative imaging studies and risk factors as well as the evaluation of clinical 
symptoms may be crucial to rise the suspect in the preoperative workup of pulmonary 
neuroendocrine tumors [37-39]. The concomitant presence of multifocal microscopic pulmonary 
neuroendocrine proliferation should warn the surgeon to program a close radiological follow-up 
with the oncological support in case of lymph nodal metastatic involvement [22]. In the PNECH 
setting, high resolution CT scan with espiratory study plays a role in detecting mosaic attenuation, 
bronchial wall thickening, air trapping and bronchiectasis in association to pulmonary nodules 
[20,24,39,40]. In our case series, only 11 of 41 patients with multicentric forms had multiple 
nodules in the preoperative CT scan; this data confirms that CT scan is insufficient to establish a 
definitive diagnosis, as radiological findings are aspecific, thus histology is always required [39]. 
Concerning nuclear medicine imaging, 18FDGPET/CT may fail to detect multifocal proliferations 
and nodal involvement as TC are characterized by low proliferation index [22]. Since most patients 
with TC express somatostatin receptors, techniques with radiolabeled somatostatin analogs instead 
are helpful both for staging and to predict the response to peptide receptor radiotargeted therapy 
[41], furthermore 68GaDOTATATE-PET/CT is preferable to Octreoscan because it is characterized 
by higher sensitivity and specificity [42]. In the present paper, TC with MNEP are characterized 
by higher rates of nodal involvement and worst prognosis; this data suggests to perform nuclear 







The operative strategy in MNEP 
Surgical resection, more or less conservative, along with lymph-nodal dissection is considered the 
gold standard for typical lung carcinoid [26]. Although lobectomy or bilobectomy are the 
predominant choices among the other available techniques, there is a tendency towards 
conservative surgery. The main concern in surgical treatment of TC is to avoid unnecessary 
removal of functioning pulmonary tissue. However, sublobar resections performed electively, are 
questionable because satisfactory lymphadenectomy cannot be achieved particularly of the 
intraparenchymal nodes.  
In our multicenter experience, if the surgical resection was performed with lymphadenectomy 
(92%) we sought a significant result compared to the absence of it (p=0.035). Due to the absence 
of pathological lymph-nodes during the pre-operative radiological workup and to the frequency of 
sub-lobar resections, we performed more often sampling (39.3%) compared to the systematic 
(26.9%) and lobe-specific (26.1%). MNEP entails a more complex pattern of multiple synchronous 
pre-invasive/invasive lesions, a higher risk of lymphatic spread, and the worst prognosis according 
to our results. Therefore, when diagnosed pre-operatively, it should consider more conservative 
lung resections to maintain a proper respiratory function in PNECH patients and the view of 
possible future surgical resections. Likewise, an adequate lymph-nodal dissection should be 
considered crucial in this setting. 
 







 The pathological assessment of the specimen  
A high standard pathology practice is required to diagnose MNEP, with routine detailed 
examination of the non-tumorous parenchyma away from the TC [43,44]. TC and tumorlets arising 
in the background of PNECH (and consequently MNEP) should not be regarded as a metastatic 
spread, but as synchronous multiple primaries [16,22]. Moreover, the presence of a PNECH to 
tumorlet progression sequence is also reassuring of a primary multifocal disease. Pathological 
examination is considered the gold standard for the diagnosis, anyways when widespread 
pulmonary neuroendocrine cells proliferation is denoted in the non-neoplastic lung surrounding a 
TC but the diagnosis of DIPNECH is not certain, a high-resolution CT may be useful [20]. 
 
Post-operative follow-up strategy and tools in case of MNEP  
From a clinical standpoint our results may suggest that potential underlying triggers leading to 
MNEP, seem to play a role in the tumor aggressiveness despite their overall small tumor size, 
earlier tumor stage and low-grade proliferative features. Thus, even in well-differentiated 
pulmonary neuroendocrine tumors, an accurate follow-up plays a crucial role [45]. In addition, the 
frequent association with peripheral tumor location and advanced age is of clinical interest. 
Detection of such patients with smaller tumor size and earlier tumor stage may be explained due 
to frequent respiratory symptoms as seen in patients with DIPNECH. In contrast to isolated TC, 
which may be diagnosed in the third decades, the low frequency of central tumors and the latency 
of the underlying potential triggers leading to TC and MNEP may also explain the fact that the 
diagnosis of patients with MNEP+TC occurs more frequently in advanced age.  
Moreover, the current series showed the presence of statistically significant association of 
asthma/bronchitis, work exposure to inhalant agents, emphysema, fibrosis and inflammatory status 
and respiratory insufficiency with MNEP+TC. The lack of association for smoking and GERD 
also distinguishes such manifestations. 
While the role of previous triggers remains to be further validated in other series, the well-known 
role of pulmonary neuroendocrine cells as chemo- and baroreceptors [45,46] may explain the 
relationship of some previous clinical states with the occurrence of MNET+TC. It remains to be 
determined whether there is a causal relationship with the development of fibrosis and hypoxic 
respiratory failure. Moreover, the release of fibrotic factors from the hyperplastic NE cells like 
histamine, serotonin, bradykinin, gastrin-releasing peptide-bombesin and other, needs to be further 
investigated. 
The complex analysis of the action of different professional inhalant, and their ability to increase 
the release of neuroendocrine secretory pattern and in particular of histamine may be also regarded 
as a possible co-factor in the development of respiratory symptoms, fibrosis and pulmonary 
insufficiency [15-18].  
From a surgical standpoint, the concomitant presence of MNEP should warn the surgeon to 
program a close and protracted follow-up though the modality and timing of examinations are not 
standardized [22,26]. Although most patients with MNEP remain stable over many years, few of 
them experience disease progression, which can be managed with the administration of 
somatostatin analogs or redo surgery [22,39]. In our case series, one patient underwent 
lingulectomy for MNEP progression six years after right upper lobectomy; in this setting, indeed, 
parenchymal-sparing surgery should be preferred to lobar resection. Eventually, in selected 
patients with radiological and clinical DIPNECH evolution with severe airflow obstruction, lung 
transplantation may be indicated [24,39]; in the current series, five patients underwent bilateral 
lung transplantation, but they were excluded from the study because of the residual absent native 






MNEP in association with a synchronous TC seems to be a negative prognostic factor and close 
postoperative surveillance should be advised. Since the preoperative confirmation of MNEP can 
be challenging, pathologists provide additional value for the dynamic risk stratification of patients 
with well-differentiated pulmonary neuroendocrine tumors by performing a careful assessment of 
the non-tumorous lung parenchyma. However, the suspicion of MNEP during the pre-operative 
setting should be careful evaluated enabling possible changes in the surgical strategy. The 
association MNEP + TC appears to have distinct clinicopathological correlations in elderly 
patients with respiratory symptoms and may result in early tumor detection. The significant 
involvement of inhalant exposure rather than active/passive smoking history and GERD, might be 
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Fig. 2 Flow chart of the patient’s selection. In this study, 36 patients with multifocal microscopic pulmonary 












Centre    0.39 
   Perugia 135(58) 114(59) 21(51)  
   Toronto 99(42) 79(41) 20(49)  
Age categories     0.022 
   <=65 155(66) 133(69) 22(54)  
   >65 79(34) 60(31) 19(46)  
Age at diagnosis    <0.001 
   Mean+/sd 56+/15 54+/15 63+/11  
   Median  








Sex    0.3 
   Female 136(58) 109(56) 27(66)  
   Male 98(42) 84(44) 14(34)  
Smoke    0.15 
   No 80(35) 70(37) 10(24)  
   Yes 149(65) 118(63) 31(76)  
   Missing 5 5 0  
Tumor location    0.0032 
   Central 106(45) 96(50) 10(24)  
   Peripheral 128(55) 97(50) 31(76)  
Primary tumor location    0.24 
   Bronchus 12(5) 10(5) 2(5)  
   Lower 104(44) 89(46) 15(37)  
   Middle 47(20) 34(18) 13(32)  
   Upper 71(30) 60(31) 11(27)  
Surgery    0.12 
   Lobar + 
Bronchoplastic/Sleeve 
187(79) 159(83) 28(68)  
   Pneumonectomy 12(5) 10(5) 2(5)  
   Wedge + Sub-lobar 35(15) 24(12) 11(27)  
Lymphadenectomy    0.035 
   No 19(8) 12(7) 7(17)  

















Pt    0.011 
   Mean+/-sd 20.4+/-11.7 21.3+/-11.7 16.2+/-10.9  
   Median  








pN+ 20(8.5) 14 (7.2) 6 (14.6) 0.02 
N1 13(5.5) 6(3.1) 4(9.7)  
N2 10(4.2) 8(4.1) 2(4.8)  
8th AJCC staging    0.041 
   I/II 204(87) 172(89) 32(78)  
   III 11(5) 9(5) 2(5)  
   X 19(8) 12(6) 7(17)  










Fig.3 The overall survival and progression free rate curves for MNEP+TC (dashed line) and TC (continuous line) in 




Fig.4 The Forest Plot displays the estimated results pooled by two groups (MNEP+TC vs TC). MNEP+TC: multifocal 













































































































































Author Year Main topic 
Statistical 
analysis method 
N° of cases M/F Location Clinical setting Smoke COPD 
Additional CT 
scan nodules 
N+ OS 10 years Outcome Descriptive conclusion 
Miller RR 1995 Pathology Descriptive 19/25 (76%) 2/17 Peripheral incidental finding 5 6 4 na na na 
Multicentric neuroendocrine cell 
proliferation is common in patients with 
peripheral carcinoid tumor of the lung 
Aubry MC 2007 
Surgery 
Clinical 
Descriptive 19/28 (67.8%) 2/26 96% peripheral 
43% cough, 2 Cushing 
Syndrome 




Most patients with tumorlets discovered 
in surgical lung specimens have 
associated peripheral carcinoid tumors. 
Davies SJ 2007 Clinical Descriptive 13/19 (68.4%) 4/15 na 
Dyspnea, cough, pain, 
hemoptysis 
17 8 na na na 
11 stable 
1 declined 
DIPNECH seems to be more common 
than thought and may be associated 
with atypical carcinoids. 
Rizvi SMH 2009 Pathology Fisher exact text 41/144 (28.5%) na 
62% central 
43% peripheral 
Na 10 21 na na na na 
There is a statistically significant 
increase in the frequency of NEH in 
TCs when compared to other lung 
tumors. 
Ferolla P 2009 Clinical 
Kaplan-meier + 
Cox regression 
14/123 (11.4%) 59/64 
62 central 
61 peripheral 




A statistically significant negative 
impact of multicentric forms on overall 
survival was evidenced 
Nassar AA 2011 Review Descriptive 10/25 (40%) 2/23 na 
Cough, dyspnea, 
wheezing 
8 13 15 na na 
6 improved 7 
stable 
4 declined 
The majority of patients diagnosed with 
DIPNECH are middle-aged females 






Chi-square 30/70 (42.8%) 9/61 na 
Dyspnea, cough, 
wheezing 
na 6 23 1 na 
21 stable 
5 declined 
The presence of 5 or more NE cells, 
singly or in clusters, located within the 
basement membrane of the bronchiolar 
epithelium of at least 3 bronchioles, 
combined with 3 or more carcinoid 




2015 Review Descriptive 109/199 (54.8%) na na 
Cough, dyspnea, 
others 
53 6/30 na na na 
13 improved 
114 stable  
30 declined 
In patients with DIPNECH who present 
with carcinoid tumor, tumorlets and 
NECH, it is logical to assume that the 
condition is probably preneoplastic and 
that the carcinoid tumor evolved from a 
intraepithelial NECH. 




Student t test, 
Fisher exact test 
13 (100%) 11/2 na 
Cough, dyspnea, 
incidental finding 
9 8 6 na na na 
Symptomatic patients with DIPNECH 
are younger and have a higher number 
of foci of linear neuroendocrine 
proliferation and tumorlets. Incidental 
DIPNECH is commonly found in 
patients diagnosed with pulmonary 
adenocarcinoma. 
Mengoli MC 2018 
Clinical 
Pathology 
Fisher exact text, 
Mann-Withney, 
Kruskal-Wallis test 
151 (100%) 77/74 
82 central 
69 peripheral 
Dyspnea, cough, other 50 36 10 3 na na 
DIPNECH with airway disease differs 
significantly from sporadic carcinoids 
with or without NECH in terms of 
demographical, clinical, radiological 
and immunopathological findings. 







28/42 (66.6%) 2/40 na 
Cough, dyspnea, 
fatigue 
10 na na na na 
32 mproved 
with SSA 
In patients with DIPNECH who have 
respiratory symptoms that are 
uncontrolled by conventional 
medications, SSA treatment palliates 
symptoms in most cases with a 
relatively low rate of toxicity. 
 
Tab. 3 All reported cases in the Literature of multifocal microscopic pulmonary neuroendocrine proliferations (more than 10 cases).  
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Background. Clinical significance of multifocal pulmonary neuroendocrine proliferations 
(MNEP), including tumorlets and pulmonary neuroendocrine cell hyperplasia, in association with 
Typical Carcinoid (TC), is still debated.  
Methods. A large retrospective series of TC with long-term follow-up data prospectively collected 
from two institutions was evaluated. Recurrence or new TC development was followed-up. 
Patients with TC alone and MNEP+TC were compared.  
Results. 234 TC patients undergone surgery were included: 41 MNEP+TC (17.5%) and 193 TC 
alone (82.5%). In the MNEP+TC group older age (p<0.001), peripheral tumors (p=0.0032), 
smaller tumor size (p=0.011) and lymph-nodal spread (p=0.02) were observed in comparison with 
TC group. Relapses occurred in 8 patients (19.5%) in the MNEP+TC group and in 7 (3.6%) of the 
TC group. The 10-years progression-free survival were 96.1% in TC and 83.8% in MNEP+TC 
(p<0.001). After matching, in 36 pairs of patients a significantly higher 5-years progression-free 
survival was calculated for TC group (p<0.01). Furthermore the odds of belonging to MNEP+TC 
group was higher with work-related exposure to inhalant agents (p=0.008), asthma/bronchitis 
(p=0.002), emphysema, fibrosis and inflammatory status (p=0.032), micronodules on the chest CT 
scan and respiratory insufficiency (p=0.036).  
Conclusions. The identification of MNEP requires careful pathological examination and 
postoperative follow-up. MNEP seems to be an adverse prognostic factor in patients with 
synchronous TC. Therefore, suspicion of MNEP during the pre-operative assessment should not 
be underestimated, enabling changes in the surgical strategy.  
 
 
